Literature DB >> 22153707

Randomized, controlled trial of a sustained delivery formulation of 5-fluorouracil for the treatment of failing blebs.

Arun Kumar Narayanaswamy1, Kelvin Lee, Ma Zhen, Jocelyn Chua, Shu Ming Chai, Pui Yi Boey, Ce Zheng, Tin Aung, Subramanian Venkatraman, Tina Tzee Ling Wong.   

Abstract

PURPOSE: To determine the efficacy of a subconjunctival injection of hyaluronic acid (HA) with 5-fluorouracil (5FU) formulation as an adjunct in reviving bleb function by needling.
DESIGN: Prospective, randomized, controlled trial. PARTICIPANTS: Fifty patients with previous trabeculectomy and scheduled by the managing physician for a needling intervention.
METHODS: One eye of each patient was randomized to receive needling with HA-5FU mixture or needling with subconjunctival injection of 5FU solution alone. MAIN OUTCOME MEASURES: The primary outcome was the percentage of subjects with an intraocular pressure (IOP) <15 mmHg without any medications at 3 months. Secondary outcomes included the need for additional needling procedures and changes in bleb morphology.
RESULTS: Forty-nine subjects (25 in the HA-5FU group and 24 in the 5FU group) completed 3 months of follow-up. At baseline, there was no significant difference between the groups in terms of demographic features, subtype of glaucoma, vertical cup-to-disc ratio, or visual field indices. The mean number of glaucoma medications at baseline was higher in the 5FU group (0.8±1.1 [mean ± standard deviation] vs. 0.2±0.6, P = 0.04). An IOP <15 mmHg without medications was reached in 48.0% of subjects in the HA-5FU group and in 33.3% of subjects in the 5FU group (P = 0.2). At 3 months, both groups demonstrated a significant decrease in IOP from baseline (HA-5FU: decrease of 5.9 mmHg [95% confidence interval, 3.4-8.4]; 5FU: decrease of 6.0 mmHg [95% confidence interval, 3.2-8.2]; P<0.001 for both). Intergroup comparisons for IOP change from baseline was not significant (P = 0.9). However, repeat needling was required more frequently in the 5FU group compared with the HA-5FU group (50.0% vs. 12.0%; P = 0.004). There were no significant differences in the number of reported adverse events, bleb vascularity, or morphology between the 2 groups.
CONCLUSIONS: Subconjunctival injection of HA-5FU to revive bleb function after bleb needling is as effective as 5FU solution. Fewer repeat needlings were required after treatment with HA-5FU, suggesting that the use of a combined formulation of HA-5FU may improve the overall outcomes of bleb needlings.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22153707     DOI: 10.1016/j.ophtha.2011.07.053

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  3 in total

1.  Bleb needling outcomes for failed trabeculectomy blebs in Asian eyes: a 2-year follow up.

Authors:  Andrew S H Tsai; Pui Yi Boey; Hla M Htoon; Tina T Wong
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

2.  Prospective pilot study comparing deep sclerectomy outcomes with a long-term and intense corticosteroid treatment versus a standard one.

Authors:  Aitor Lanzagorta-Aresti; Marta Perez-Lopez; Juan Maria Davo-Cabrera; Elena Palacios-Pozo
Journal:  BMJ Open Ophthalmol       Date:  2018-10-31

Review 3.  Wound Healing Modulation in Glaucoma Filtration Surgery- Conventional Practices and New Perspectives: Antivascular Endothelial Growth Factor and Novel Agents (Part II).

Authors:  Jennifer C Fan Gaskin; Dan Q Nguyen; Ghee Soon Ang; Jeremy O'Connor; Jonathan G Crowston
Journal:  J Curr Glaucoma Pract       Date:  2014-06-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.